Anzeige
Mehr »
Donnerstag, 04.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JP9Y | ISIN: DK0060336014 | Ticker-Symbol: NZM2
Tradegate
04.09.25 | 19:00
54,42 Euro
+1,00 % +0,54
1-Jahres-Chart
NOVONESIS A/S Chart 1 Jahr
5-Tage-Chart
NOVONESIS A/S 5-Tage-Chart
RealtimeGeldBriefZeit
54,3254,4619:46
54,3254,4619:46

Aktuelle News zur NOVONESIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiNovonesis (Novozymes A/S): Trading by management and close relations of management4
28.08.Novonesis (Novozymes A/S): Amendment: Trading by management and close relations of management4
28.08.Novonesis (Novozymes A/S): Trading by management and close relations of management4
28.08.JPMorgan senkt Kursziel für Novonesis wegen höherer Investitionsprognose auf 512 DKK16
28.08.Novonesis stock price target lowered to DKK512 by JPMorgan on capex outlook3
26.08.Novonesis stock price target lowered to DKK490 by Deutsche Bank14
NOVONESIS Aktie jetzt für 0€ handeln
26.08.Deutsche Bank senkt Kursziel für Novonesis auf 490 DKK25
22.08.Novonesis (Novozymes A/S): Trading by management and close relations of management7
21.08.Novozymes A/S Non-GAAP EPS of €0.78, revenue of €2.09B24
21.08.Novonesis (Novozymes A/S): Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%424COPENHAGEN, Denmark - August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%. Ester Baiget, President & CEO: "I'm very pleased with 9% organic...
► Artikel lesen
21.08.Novonesis (Novozymes A/S): Interim report H1 20251789% organic sales growth in H1 and FY outlook range narrowed to 6-8% Ester Baiget, President & CEO: "I'm very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions...
► Artikel lesen
20.08.Novonesis (Novozymes A/S): 2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement509COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its 'GROW' strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant...
► Artikel lesen
21.07.Novonesis (Novozymes A/S): Major shareholder announcement27
07.07.Novonesis (Novozymes A/S): Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe578Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains and...
► Artikel lesen
30.06.Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program4
23.06.Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program9
23.06.Novonesis (Novozymes A/S): Major shareholder announcement9
19.06.Novonesis (Novozymes A/S): Major shareholder announcement3
16.06.Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program4
12.06.Novonesis (Novozymes A/S): Major shareholder announcement6
Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1